A case report: Response to Osimertinib in non-small cell lung cancer patient with uncommon EGFR mutation
-
Published:2022-12
Issue:
Volume:8
Page:100188
-
ISSN:2666-6219
-
Container-title:Current Problems in Cancer: Case Reports
-
language:en
-
Short-container-title:Current Problems in Cancer: Case Reports
Author:
Craig Daniel J.ORCID,
Kahlon Navkirat K.,
Hamouda Danae M.
Reference18 articles.
1. Third-generation tyrosine kinase inhibitors targeting epidermal growth factor receptor mutations in non-small cell lung cancer;Barnes;Front. Oncol.,2017
2. EGFR mutations and lung cancer;da Cunha Santos;Annu. Rev. Pathol.,2011
3. Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment;Del Re;Oncotarget,2017
4. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study;Douillard;Br. J. Cancer,2014
5. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS);Fukuoka;J. Clin. Oncol.,2011